5/24/2022 7:04:09 AM
Alnylam Presents New Results From ILLUMINATE-C Phase 3 Study Of Lumasiran In Advanced Primary Hyperoxaluria Type 1
5/18/2022 8:04:41 AM
Alnylam : Canada Authorizes OXLUMO For Treatment Of Primary Hyperoxaluria Type 1 To Lower Urinary Oxalate Levels
4/28/2022 8:05:22 AM
Alnylam Pharmaceuticals Q1 Net Loss Widens To $240.3 Mln From $200.3 Mln Last Year
4/5/2022 4:07:55 PM
Alnylam Announces Retirement Of Steven Paul From Board Of Directors
4/4/2022 7:37:42 AM
Alnylam : FDA Extends Review Timeline Of NDA For Vutrisiran To July 14, 2022; No Additional Clinical Data Requested
3/17/2022 7:38:19 AM
Alnylam Pharma Says Filed Patent Infringement Suits Against Pfizer And Moderna On MRNA COVID-19 Vaccines
3/16/2022 7:33:39 AM
Alnylam Issues 2021 Corporate Responsibility Report
3/1/2022 7:12:24 AM
Alnylam Pharma Says FDA Accepts SNDA For OXLUMO For Advanced Primary Hyperoxaluria Type 1
2/10/2022 8:09:06 AM
Alnylam Pharma Q4 GAAP Loss Per Share $2.16; Non-GAAP Loss Per Share $1.69